Dr. Morgan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
# SW530
Boston, MA 02115Phone+1 617-632-5204Fax+1 617-632-3408
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1993 - 1996- Brigham and Women's HospitalResidency, Internal Medicine, 1990 - 1993
Harvard Medical SchoolClass of 1990
Certifications & Licensure
MA State Medical License 1993 - 2025- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) Start of enrollment: 2006 Jun 01
Publications & Presentations
PubMed
- 235 citationsMulticenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor SarcomasSuzanne George, Priscilla Merriam, Robert G. Maki, Annick D. Van den Abbeele, Jeffrey T. Yap
Journal of Clinical Oncology. 2009-07-01 - 53 citationsA Phase II trial of gemcitabine for metastatic neuroendocrine tumors.Matthew H. Kulke, Haesook T. Kim, Jeffrey W. Clark, Peter C. Enzinger, Thomas J. Lynch
Cancer. 2004-09-01 - 10 citationsConcurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST.Inga-Marie Schaefer, Matthew L Hemming, Meijun Z Lundberg, Matthew P Serrata, Isabel Goldaracena
British Journal of Cancer. 2022-11-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
